Sign in
CompletedNo phase

The Effect of Laparoscopic Splenectomy on the Immune Function for Cirrhosis Patients

Key facts

Who runs it
Northern Jiangsu People's Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
21 people enrolled
Started
1 Mar 2022
Ended
30 Nov 2024
Type of study
Interventional
Treatments tested
  • Laparoscopic splenectomy
Record updated
19 March 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • A clinical, radiological or histologic diagnosis of cirrhosis of any etiology
  • Splenomegaly with secondary hypersplenism, Platelet count < 50*10\^9/L
  • Informed consent to participate in the study

Who cannot take part

  • Hepatocellular carcinoma or any other malignancy,
  • Recent peptic ulcer disease
  • History of Hemorrhagic stroke
  • Uncontrolled Hypertension
  • Bleeding portal hypertension
  • Human immunodeficiency virus (HIV) infection
  • Child-Pugh grade C
  • Pregnancy

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

In this study, the investigators compared the improvement of and azygoportal disconnection related indicators in patients with liver cirrhosis after laparoscopic splenectomy. To determine whether surgical treatment can help enhance postoperative immune function and improve patient prognosis.

The group in the trial

  • Laparoscopic splenectomyTreatment being tested

    The laparoscopic splenectomy is performed by the same surgical team.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
19 March 2025